Community Practice Connections: Nursing Opportunities to Improve Outcomes with the Advent of PARP Inhibitors in the Care of Women's Cancers

Community Practice Connections: Nursing Opportunities to Improve Outcomes with the Advent of PARP Inhibitors in the Care of Women's Cancers is organized by Physicians' Education Resource LLC (PER) and will be held from Jun 29, 2018 - Jun 29, 2019.

The target audience for this medical event is directed toward all attendees of the ONS 43rd Annual Congress, including nurses and other healthcare professionals with an interest in the treatment of patients with breast and ovarian cancers. This CME Conference has been approved for a maximum of 1.5 Credits.

Description:
The advent of PARP inhibitor therapy is transforming the treatment landscape for your patients with breast and ovarian cancers. Because of the frequent and unique opportunities that you have to improve clinical outcomes for your patients, we have developed an engaging multimedia educational activity to enhance your understanding of the effectiveness of these new strategies, methods to mitigate and manage predictable and distinct adverse events, and the importance of counseling your patients concerning the use of these novel approaches, which are very different from traditional oncology agents in several aspects, including the way that they work and the efficacy and safety profiles that they carry.

This activity, featuring video commentary from a multidisciplinary panel of clinical experts, will present best practices that you can utilize in the treatment, management, and overall care of patients with breast and ovarian cancers who may be candidates for PARP inhibitor therapy. The latest clinical evidence will be discussed, as well as practical considerations to help you optimize patient management.

Learning Objectives:
At the conclusion of this activity, participants should be better prepared to:
• Outline the underlying mechanisms by which PARP inhibitors exert their activity in the treatment of cancer
• Delineate key concepts and findings from pivotal trials that have evaluated PARP inhibitors for the treatment of ovarian and breast cancers
• Practically apply knowledge of PARP inhibitor strategies to real-world clinical scenarios in which nurses counsel patients with ovarian and breast cancers
• Develop processes to proactively mitigate the impact of adverse events in the treatment of ovarian and breast cancers